In This Section

Contact
E-mail
bellb [at] email.chop.edu
Location - People View

2716 South Street
Philadelphia, PA 19146
United States

Related Topics

COVID-19: Information for NIH Applicants and Recipients

Published on
Apr 1, 2020
AddtoAny
Share:

Please find information and guidance below from the National Institutes of Health as it relates to the current COVID-19 public health emergency. If you have specific questions on this guidance, please reach out to your Sponsored Projects Officer (SPO).

The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the coronavirus.

Health and Human Services Secretary Alex M. Azar II declared a public health emergency for COVID-19 retroactive to January 27, 2020. Due to the potential exceptional impact, the NIH is offering assurance to its recipient community that NIH will be doing its part to help you continue your research. During this rapidly evolving situation, updated guidance and information will be provided as it becomes available.

Guidance

Proposal Submission & Award Management

Human Subjects & Clinical Trials

Peer Review

  • Based on NIH Guidance on Travel and Meetings, in-person NIH peer review meetings are being held in alternate formats. Scientific review officers will be in contact with peer reviewers about these changes.

Funding Opportunities Specific to COVID-19

National Institute of Allergy and Infectious Diseases (NIAID)

NOT-AI-20-030
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
National Institute of General Medical Sciences (NIGMS)

NOT-HL-20-757
Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
National Heart, Lung, and Blood Institute (NHLBI)

NOT-DA-20-047
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
National Institute on Drug Abuse (NIDA)

FAQs

Resources